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Aims: Annexin 1 (ANXA1), a member of the annexin
family of calcium-binding and phospholipid-binding
proteins, is a key mediator of the anti-inflammatory
actions of steroid hormones. We have previously
demonstrated that, in the human lymphoblastic
CCRF-CEM cell line, both the synthetic glucocorticoid
hormone, dexamethasone (Dex), and the estrogen
hormone, 17b-estradiol (E2b), induce the synthesis of
ANXA1, by a mechanism independent of the activa-
tion of their nuclear receptors. Recently, it was
reported that the gene coding for ANXA1 contains a
cAMP-responsive element (CRE). In this work, we
investigated whether Dex and E2b were able to induce
the activation of CRE binding proteins (CREB) in the
CCRF-CEM cells. Moreover, we studied the intracellu-
lar signalling pathways involved in CREB activation
and ANXA1 synthesis in response to Dex and E2b;
namely, the role of cAMP and the p38 mitogen-
activated protein kinase (MAPK).
Results: The results show that Dex and E2b were as
effective as the cAMP analogue, dBcAMP, in inducing
CREB activation. On the contravy, dBcAMP induced
ANXA1 synthesis as effectively as these steroid
hormones. Furthermore, the cAMP antagonist, Rp-8-
Br-cAMPS, and the specific p38 MAPK inhibitor,
SB203580, effectively prevented both Dex-induced,
E2b-induced and dBcAMP-induced CREB activation
and ANXA1 synthesis.
Conclusions: Taken together, our results suggest that,
in CCRF-CEM cells, Dex-induced and E2b-induced
ANXA1 expression requires the activation of the
transcription factor CREB, which in turn seems to
be mediated by cAMP and the p38 MAPK. These
findings also suggest that, besides the nuclear steroid
hormone receptors, other transcription factors,
namely CREB, may play important roles in mediating
the anti-inflammatory actions of glucocorticoids and
oestrogen hormones.
Key words: Annexin 1, CREB, 17b-Estradiol, Dexametha-
sone, cAMP, p38 MAPK
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Introduction
Annexin 1 (ANXA1) (also known as lipocortin 1) is a
member of the annexin family of calcium-binding
and phospholipid-binding proteins,1,2 which is con-
stitutively expressed in many human cells, particu-
larly in polymorphonuclear leukocytes.1,3 Recently,
we observed that ANXA1 is also constitutively
expressed in a human lymphoblastic T cell line, the
CCRF-CEM cell line.4 Although its biological role is
still incompletely characterised, ANXA1 is considered
an endogenous anti-inflammatory effector that med-
iates at least some of the anti-inflammatory actions of
the glucorticoid (GC) hormones; namely, the inhibi-
tion of phospholipase A2, with the consequent
suppression of prostaglandin and leukotriene pro-
duction,1 the inhibition of superoxide generation,5
the inhibition of the activation, transmigration and
phagocytic ability of neutrophils.3 Recently, ANXA1
has also been shown to mediate the inhibitory effect
of GCs on the expression of cyclooxygenase-2 (COX-
2),68 an enzyme required for prostaglandin produc-
tion and also involved in cell proliferation.9,10
Furthermore, some of the anti-inflammatory effects
attributed to 17b-estradiol (E2b), the most potent
oestrogen hormone, are identical to those exerted by
ANXA1, suggesting that this protein may also mediate
the anti-inflammatory actions of E2b.11,12
In resting cells ANXA1 is an intracellular protein,
being secreted and resynthesised upon stimulation.
Once in the extracellular medium, ANXA1 binds, in a
paracrine or autocrine way, to specific plasma
membrane binding sites, which are considered to
mediate its biological actions.5,13 Consistent with the
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notion that ANXA1 mediates some of the anti-
inflammatory actions of GCs, these hormones, most
remarkably the synthetic GC dexamethasone (Dex),
have been shown to potently induce ANXA1 secre-
tion and synthesis in many different cells.14,15 Our
own observations also show that both Dex16 and E2b4
induce the rapid secretion of ANXA1, followed by its
de novo synthesis, in the human lymphoblastic CCRF-
CEM cells.
The intracellular signalling pathways utilised by
either the GC or the oestrogen hormones to induce
ANXA1 synthesis are still poorly understood. Many
actions of these hormones are mediated through
genomic mechanisms involving their respective nu-
clear receptors, which, upon binding the hormone,
act as transcription factors directly modulating the
transcription of genes containing in their promoter
regions either a GC responsive element (GRE) or an
oestrogen responsive element.17,18 Using the potent
GC receptor antagonist RU486 (mifepristone), some
studies showed that, in some cells, the synthesis of
ANXA1 is dependent on GC receptors,2,19 whereas
the opposite was found in other cells.20,21 Therefore,
some authors have suggested that the putative GRE
that is present in the promoter region (intron I) of the
ANXA1 gene is non-functional.22,23 In our previous
work, we also found no evidence supporting the
involvement of such nuclear hormone receptors in
either Dex-induced or E2b-induced ANXA1 synthesis
in CCRF-CEM cells.4,16
Besides the putative GRE, it was recently shown
that the promoter region of the ANXA1 gene contains
a cAMP-responsive element (CRE) and that a CRE-
binding protein (CREB) is required for either Dex-
induced or cAMP-induced ANXA1 synthesis.22
Furthermore, Dex and E2b have also been shown to
induce the transcription of several genes by activating
CREB.22,24,25
The phosphorylation and consequent activation of
CREB can be regulated by several intracellular
signalling pathways. Among those, cAMP26,27 and
the p38 mitogen-activated protein kinase (MAPK)28,29
seem to play crucial roles in the activation of CREB in
different cells. Interestingly, various studies showed
that Dex and E2b can stimulate adenylate cyclase
activity, thus increasing the production of cAMP,3033
which is also an inducer of ANXA1 synthesis in some
cell types.22,34,35 Moreover, recent reports indicate
that, in different cells, Dex and E2b can up-regulate
the activity of the p38 MAPK.3638
In an attempt to understand the mechanisms by
which Dex and E2b induce the synthesis of ANXA1,
we have investigated the ability of these two steroid
hormones to activate CREB in the CCRF-CEM cells.
Moreover, to further elucidate the signalling path-
ways involved, we also studied the role of cAMP and
of the p38 MAPK on Dex-induced and E2b-induced
CREB activation and ANXA1 expression.
Materials and methods
Chemicals
The human CCRF-CEM acute T lymphoblastic leu-
kaemia cell line was purchased from American Type
Culture Collection (Rockville, MD, USA). Foetal calf
serum (FCS) was obtained from Biochrom (Berlin,
Germany). Dibutyryl-cAMP (dBcAMP) was from
BIOMOL (USA). Adenosine 3?,5?-cyclic monopho-
sphorothioate, 8-bromo, Rp-isomer, sodium salt
(Rp-8-Br-cAMPS) and SB203580 were purchased
from Calbiochem (San Diego, CA, USA). The protease
inhibitor cocktail was obtained from Roche (Man-
heim, Germany). The oligonucleotide probes were
from Santa Cruz (Santa Cruz, CA, USA). [g-32P]
adenosine triphosphate, T4 polynucleotide kinase
and poly (dI-dC) /(dI-dC) were obtained from Phar-
macia Biosciences (Piscataway, NJ, USA). The mouse
monoclonal antibody against ANXA1 (Clone Lipo
105) was purchased from BabCO (CA, USA). The
FITC-conjugated rabbit anti-mouse antibody and the
normal rabbit serum were obtained from DAKO
(Copenhagen, Denmark). All other reagents were
from Sigma Chemical Co. (St Louis, MO, USA).
Culture conditions
The human CCRF-CEM acute T lymphoblastic leu-
kaemia cell line was maintained in RPMI medium
supplemented with 10% (v/v) FCS, 100 mg/ml strep-
tomycin and 100 U/ml penicilin, at 378C, in an
atmosphere of 5% CO2/95% air. Prior to any treat-
ments, CCRF-CEM cells were plated at 5/106 cells/
well, in six-well culture plates, in RPMI supplemented
with antibiotics and 0.5% FCS, for at least 5 h, and
maintained in these conditions thereafter. In each
experiment, controls consisting of cells incubated in
the corresponding volume of culture medium plus
the appropriate vehicle were always included.
Cell viability
The viability of CCRF-CEM cells, under the various
experimental conditions, was always assessed by the
trypan blue exclusion method and the 3-(4,5-di-
methylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide
(MTT) reduction assay. Assessment of MTT reduction
by metabolically active cells was made by a colori-
metric assay, as previously described.39
Preparation of cytoplasmic and nuclear extracts
After washing with ice-cold phosphate-buffered sal-
ine (PBS), the cells were lysed in ‘buffer 1’ (10 mM
NaCl, 3 mM MgCl2, 0.5% (v/v) Nonidet P-40, 1 mM
dithiothreitol, 0.1 mM phenylmethylsulfonylfluoride,
10 mM Tris/HCl, pH 7.5, and the protease inhibitor
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cocktail) and incubated on ice, for 15 min. After brief
vortexing, the lysates were centrifuged at 2300/g ,
for 10 min, at 48C. The supernatants, cytoplasmic
extracts, were collected and stored at /708C until
further use. The pellets obtained were resuspended
in ‘buffer 2’ (300 mM NaCl, 3 mM MgCl2, 20% (v/v)
glycerol, 1 mM dithiothreitol, 0.1 mM phenylmethyl-
sulfonylfluoride, 0.2 mM ethylenediamine tetraacetic
acid (EDTA), 20 mM HEPES buffer, pH 7.5, and the
protease inhibitor cocktail), incubated on ice for 45
min and centrifuged at 12,000/g , for 20 min, at 48C.
The supernatants, nuclear extracts, were also col-
lected and stored at /708C until further use. The
protein concentration of the extracts was determined
using the bicinchoninic acid/copper (II) sulphate
protein assay kit.
Electrophoretic mobility shift assay
The oligonucleotide probes containing either the
consensus binding sequence corresponding to the
CRE (5?-AGA GAT TGC CTG ACG TCA GAG AGC
TAG-3?) or a mutated inactive form of this oligonu-
cleotide (5?-AGA GAT TGC CTG TGG TCA GAG AGC
TAG-3?) were end-labelled with [g-32P] adenosine
triphosphate, by the T4 polynucleotide kinase, and
purified through Sephadex G-50 spin columns.
Nuclear extracts (12.5 mg protein) were incubated,
for 40 min, at 48C, with 100,000 cpm of the [g-32P]-
labelled oligonucleotide, in a buffer containing 100
m/ml poly(dI-dC) /poly(dI-dC), 20 mM HEPES (pH
7.9), 1 mM MgCl2, 4% (v/v) Ficoll 400, 0.5 mM
dithiothreitol, 50 mM KCl, and 1 mg/ml barine serum
albumin. The DNA/protein complexes were re-
solved by electrophoresis on 7% non-denaturating
polyacry-lamide gels, in a buffer system containing
0.044 M Tris/Base (pH 8.0), 4.45 mM boric acid and 1
mM EDTA, at constant voltage of 150 V, for 3 h, at
room temperature. The gels were then dried and
subjected to autoradiography. In competition experi-
ments, a 100-fold excess of unlabelled oligonucleo-
tide was added to the nuclear extracts immediately
before the addition of the radiolabelled probe.
Immunocytochemistry assay
After washing in ice-cold PBS, the cells were spread
on poly-D-lysine-coated glass slides and air-dried for
30 min. The cells were then fixed (4% (w/v)
paraformaldehyde and 2% (w/v) sucrose in PBS),
for 15 min, and permeabilised (1% Triton-XlOO in
PBS), for 5 min. Background blocking was performed
with normal rabbit serum, and detection of total
ANXA1 was performed by incubation with a mouse
monoclonal anti-ANXA1 antibody (4 mg/ml). After
extensive rinsing in PBS, the cells were incubated
with a FTTC-conjugated rabbit anti-mouse antibody.
We have previously confirmed the specificity of this
anti-ANXA1 antibody by western blot analysis.4,16
Serum and antibodies were diluted in PBS with 0.5%
(w/v) bovine serum albumin and 0.2% (v/v) Tween-
20, and all the incubations were performed at room
temperature, in a humidified chamber. Control ex-
periments for non-specific binding were performed
in parallel by omission of the primary antibody.
Results
Dex, E2b and dBcAMP induce CREB activation
To evaluate CREB activation we used electrophoretic
mobility shift assay (EMSA) analysis to detect the
presence of active CREB proteins, capable of forming
complexes with a [g-32P]-labelled oligonucleotide
probe containing the specific consensus binding
sequence for this transcription factor. The oligonu-
cleotide used corresponds to the CRE present in the
promoter region of target genes.
CCRF-CEM cells were cultured in RPMI medium
supplemented with 0.5% FCS, and treated with Dex
(1 mM), E2b (1 mM) or with the stable cell-permeable
cAMP analogue dBcAMP (1 mM) for 15 min, 30 min
or 1 h. The respective nuclear extracts were used for
EMSA analysis. The results obtained show the pre-
sence of retarded bands, the intensity of which was
much higher in the nuclear extracts from cells treated
with Dex (Fig. 1), E2b (Fig. 2) or dBcAMP (Fig. 3)
than in those from control untreated cells (Figs. 1/3,
lane 1). For each stimulus, the intensity of those
bands varied with the incubation time and was
maximal when the cells were treated with Dex for 1
h (Fig. 1, lane 4), E2b for 30 min (Fig. 2, lane 3), or
dBcAMP for 15 min (Fig. 3, lane 2). Therefore, for
each one of these three stimuli, the respective
optimal incubation time was used in all subsequent
experiments.
The specificity of the complexes formed was
evaluated by incubating the nuclear extracts from
Dex-treated, E2b-treated or dBcAMP-treated cells
with a [32P]-labelled mutant CREB oligonucleotide
probe that differs in two bases from the native CREB
oligonucleotide. As shown in lane 5 of Figs. 1/3, no
specific CREB complexes could be detected under
these experimental conditions. Furthermore, compe-
tition assays performed by incubation of the nuclear
extracts with the [32P]-labelled CREB oligonucleotide
probe and with a 100-fold excess of unlabelled
oligonucleotide probes, specific for either CREB,
mutant CREB or an unrelated transcription factor,
octamer (Oct-1), showed that only the unlabelled
CREB probe was effective in preventing the forma-
tion of specific complexes between the proteins
present in the nuclear extracts and the labelled
CREB probe (Figs l/3, lanes 6/8). These results
indicate that the retarded bands detected in lanes 1/4
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of the autoradiographies presented in Figs. 1/3
represent the formation of specific complexes be-
tween CREB proteins and the CREB-specific oligonu-
cleotide probe.
CREB activation, induced by Dex, E2b or
dBcAMP, is inhibited by the cAMP antagonist,
Rp-8-Br-cAMPS
In order to investigate whether cAMP is required for
the activation of CREB induced by Dex, E2b or
dBcAMP, we used the potent cAMP antagonist Rp-8-
Br-cAMPS, which is metabolically stable and cell
permeable.40 CCRF-CEM cells were pre-treated with
Rp-8-Br-cAMPS (500 mM), for l h, before the addition
of Dex, E2b or dBcAMP, and then further incubated
for l h, 30 min or 15 min, respectively. Assessment of
the cell viability by the MTT reduction assay showed
that Rp-8-Br-cAMPS did not reduce the viability of the
CCRF-CEM cells relatively to untreated cells (data not
shown), thus indicating the absence of toxic effects in
the experimental conditions used. The results pre-
sented in Fig. 4 show that pre-treatment of the cells
with Rp-8-Br-cAMPS effectively prevented Dex-in-
duced, E2b-induced and dBcAMP-induced CREB
activation, as indicated by the reduced intensity of
the bands corresponding to the specific CREB com-
plexes (lanes 3, 5 and 7). Treatment of the cells with
Rp-8-Br-cAMPS alone had no effect on the basal
activation of CREB observed in nuclear extracts from
control cells (data not shown).
ANXA1 expression, induced by either Dex, E2b
or dBcAMP, is inhibited by the cAMP antagonist
Rp-8-Br-cAMPS
ANXA1 expression was evaluated by immunocyto-
chemistry in permeabilised CCRF-CEM cells. This
method allowed us to detect total ANXA1, which
corresponds to the intracellular protein plus the
protein bound to its specific binding sites located
on the outer surface of CCRF-CEM cells plasma
membrane.
FIG. 1. Dex induces CREB activation in CCRF-CEM cells. The
cells were treated with Dex (1 mM) (lanes 2/4), for 15 min, 30
min or 1 h, or left untreated (control, lane 1). Nuclear extracts
were subjected to EMSA analysis as described in Materials
and methods. Competition experiments with a 100-fold
excess of unlabelled competitor probe relative to the labelled
CREB probe were performed using the nuclear extracts from
cells treated with Dex, for l h (lanes 6/8). EMSA analysis was
also performed using a labelled mutant CREB probe (lane 5).
The results shown are representative of three independent
experiments.
FIG. 2. E2b induces CREB activation in CCRF-CEM cells. The
cells were treated with E2b (1 mM) (lanes 2/4), for 15 min, 30
min or 1 h, or left untreated (control, lane 1). Nuclear extracts
were subjected to EMSA analysis as described in Materials
and methods. Competition experiments with a 100-fold
excess of unlabelled competitor probe relatively to the
labelled CREB probe were C performed using the nuclear
extracts from cells treated with E2b, for 30 min (lanes 6/8).
EMSA analysis was also performed using a labelled mutant
CREB probe (lane 5). The results shown are representative of
three independent experiments.
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We have previously shown that Dex significantly
increases the cellular content of ANXA1, upon
stimulation of CCRF-CEM cells for 12 h.16 Therefore,
in this work the cells were treated with Dex (1 mM),
E2b (1 mM) or dBcAMP (1 mM), for 12 h, for the
detection of total ANXA1 by immunocytochemistry.
The results obtained showed that control untreated
CCRF-CEM cells have a weak basal fluorescent
staining for ANXA1 (Fig. 5A), which corresponds to
the constitutive expression of this protein. In cells
treated with Dex or E2b, for 12 h, there was a marked
increase of the fluorescent staining for total ANXA1
(Fig. 5B,C). A similar increase of the total ANXA1
immunoreactivity was also observed in cells treated
with dBcAMP for the same time period (Fig. 5D).
Taken together, these results show that Dex, E2b and
dBcAMP increase the total cellular content of ANXA1,
indicating that these compounds induce the expres-
sion of ANXA1 in CCRF-CEM cells.
To investigate whether cAMP mediates Dex-in-
duced and E2b-induced ANXA1 expression, the cells
were pre-treated with Rp-8-Br-cAMPS (500 mM), for 1
h, before the addition of those stimuli, for another 12
h. The results presented in Fig. 5E/G show that in
cells pre-treated with Rp-8-Br-cAMPS the fluorescent
staining for ANXA1 was similar to that of control cells,
indicating that this cAMP antagonist is effective in
preventing the synthesis of ANXA1 induced by either
Dex, E2b or dBcAMP. Rp-8-Br-cAMPS alone had no
effect on the basal immunoreactivity for ANXA1 (data
not shown).
The p38 MAPK inhibitor SB203580 prevents
Dex-induced, E2b-induced and dBcAMP-induced
CREB activation and ANXA1 expression
To further elucidate the mechanism by which Dex,
E2b and dBcAMP induce CREB activation and ANXA1
expression, we studied the involvement of the p38
MAPK on this pathway. For this purpose we used
SB203580, which is a pyridinyl imidazole compound
shown to specifically inhibit the activity of the p38
MAPK.4143 SB203580 (40 mM) did not reduce the
FIG. 3. dBcAMP induces CREB activation in CCRF-CEM cells.
The cells were treated with dBcAMP (1 mM) (lanes 2/4), for
15 min, 30 min or 1 h, or left untreated (control, lane 1).
Nuclear extracts were subjected to EMSA analysis as
described in Materials and methods. Competition experi-
ments with a 100-fold excess of unlabelled competitor probe
relatively to the labelled CREB probe were performed using
the nuclear extracts from cells treated with dBcAMP, for 15
min (lanes 6/8). EMSA analysis was also performed using a
labelled mutant CREB probe (lane 5). The results shown are
representative of three independent experiments.
FIG. 4. Rp-8-Br-cAMPS inhibits Dex-induced, E2b-induced
and dBcAMP-induced CREB activation in CCRF-CEM cells.
The cells were incubated in the presence or in the absence
(control, lane 1) of the cAMP antagonist Rp-8-Br-cAMPS (500
mM), for 1 h. Then, the cells were further incubated with Dex
(1 mM), E2b (1 mM) or dBcAMP (1 mM) for l h, 30 min or 15
min, respectively. Nuclear extracts were subjected to EMSA
analysis as described in Materials and methods. The results
shown are representative of three independent experiments.
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viability of the CCRF-CEM cells, as assessed by the
MTT reduction assay (data not shown), indicating the
absence of toxic effects in the experimental condi-
tions used.
To study the involvement of the p38 MAPK on
CREB activation, CCRF-CEM cells were pre-treated
with SB203580 (40 mM), for 1 h, before the addition of
Dex (1 mM), E2b (1 mM) or dBcAMP (1 mM), and then
further incubated for the optimal time periods pre-
viously identified for each stimulus (Figs. 1/3). The
corresponding nuclear extracts were then subjected
to EMSA analysis. The results presented in Fig. 6
show that pre-treatment of the cells with SB203580
was effective in preventing CREB activation induced
by either Dex, E2b or dBcAMP, as indicated by the
reduced intensity of the bands corresponding to the
CREB specific complexes (lanes 3, 5 and 7). The
involvement of the p38 MAPK on ANXA1 expression,
induced by Dex, E2b or dBcAMP, in CCRF-CEM cells
was also evaluated by immunocytochernistry. The
results showed that pre-treatment of the cells with
SB203580 (40 mM), for 1 h, prior to the addition of
Dex (1 mM), E2b (1 mM) or dBcAMP (1 mM), for
another 12 h, effectively inhibited the increase in the
fluorescent staining for total ANXA1 (Fig. 5H/J), as
FIG. 5. Rp-8-Br-cAMPS and SB203580 inhibit the expression
of ANXA1 induced by Dex, E2b or dBcAMP in CCRF-CEM
cells. The cells were pre-treated with Rp-8-Br-cAMPS (500
mM) or with SB203580 (40 mM), for 1 h, before the addition of
Dex (1 mM), E2b (1 mM) or dBcAMP (1 mM), for 12 h. The
detection of total ANXA1 was performed by immunocyto-
chemistry, as described in Materials and methods. (A)
control, untreated cells; (B) cells treated with Dex; (C) cells
treated with E2b; (D) cells treated with dBcAMP; (E) cells
treated with Rp-8-Br-cAMPS plus Dex; (F) cells treated with
Rp-8-Br-cAMPS plus E2b; (G) cells treated with Rp-8-Br-
cAMPS plus dBcAMP; (H) cells treated with SB203580 plus
Dex; (I) cells treated with SB203580 plus E2b; (J) cells treated
with SB203580 plus dBcAMP. The results shown are repre-
sentative of three independent experiments.
FIG. 6. SB203580 inhibits Dex-induced, E2b-induced and
dBcAMP-induced CREB activation in CCRF-CEM cells. The
cells were incubated in the presence or in the absence
(control, lane 1) of the p38 inhibitor, SB203580 (40 mA), for 1
h. Then, the cells were further incubated with Dex (1 mM), E2b
(1 mM) or dBcAMP (1 mM), for 1 h, 30 min or 15 min,
respectively. Nuclear extracts were subjected to EMSA
analysis as described in Materials and methods. The results
shown are representative of three independent experiments.
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compared with cells treated with Dex, E2b or
dBcAMP in the absence of the inhibitor (Fig. 5 B/D).
SB203580 alone had no effect on either the basal
activation of CREB, or the basal expression of ANXA1
(data not shown).
Discussion
In this work, we found that both Dex and E2b induce
CREB activation, and that the cAMP analogue
dBcAMP is as effective as Dex and E2b in activating
this transcription factor and in inducing ANXA1
synthesis, in CCRF-CEM cells. We also found that
both the cAMP antagonist Rp-8-Br-cAMPS, and the
p38 MAPK inhibitor SB 203580 effectively prevent
CREB activation and ANXA1 synthesis induced by
either Dex, E2b or the cAMP analogue dBcAMP.
These results indicate that cAMP and the p38 MAPK
are both required for Dex-induced and E2b-induced
CREB activation and ANXA1 synthesis, and are also
strong evidence that CREB activation is required for
ANXA1 synthesis in these cells.
The intracellular signalling pathways involved in
the expression of ANXA1 in response to steroid
hormones are still incompletely understood.
Although some reports show that GC hormones up-
regulate ANXA1 synthesis by genomic mechan-
isms,2,19 studies in different cells indicate that this
effect is independent of the activation of nuclear GC
receptors.20,21,23 In agreement with these latter re-
sults, our previous studies also indicate that, in CCRF-
CEM cells, ANXA1 synthesis is independent of either
the nuclear GC receptors or the oestrogen recep-
tors.4,16 Recently, it was shown that the gene coding
for ANXA1, besides a putative GRE, also possesses a
specific consensus binding sequence for CREB that
was found to be essential for ANXA1 expression in a
human choriocarcinoma-derived cell line.22
Many stimuli, acting in a variety of cells, increase
the intracellular cAMP concentration, which leads to
the activation of CREB by phosphorylation of the
serine-133 residue.26,27 The results presented here
show that Dex and E2b were as effective as the cAMP
analogue dBcAMP in activating CREB (Figs. 1/3).
Although Dex and E2b mimicked the effects of
dBcAMP, both hormones required longer incubation
periods for maximal response, suggesting that cAMP
has to be produced, in response to both steroids,
before CREB activation can occur. In fact, these
findings are in agreement with studies in other cell
types showing that Dex and E2b induce the produc-
tion of cAMP, with variable kinetics, depending on
the cell type.3033 To further elucidate the role of
cAMP on Dex-induced and E2b-induced CREB activa-
tion, we used the metabolically stable cell-permeant
cAMP antagonist Rp-8-Br-cAMPS.40 Our results show
that when CCRF-CEM cells were pre-treated with the
cAMP antagonist, the activation of CREB, in response
to either Dex, E2b or dBcAMP, was efficiently
prevented (Fig. 4). Taken together, these results
indicate that, in CCRF-CEM cells, Dex-induced and
E2b-induced CREB activation is mediated by cAMP.
Effects of Dex and E2b mediated via cAMP, and
involving probably non-genomic mechanisms, have
also been reported in other cell types.25,31,44,45
The results presented in this work (Fig. 5A/C) and
in our latest works4,16 show that, in CCRF-CEM cells,
Dex and E2b induce the synthesis of ANXA1.
Additionally, we found that treatment of the cells
with dBcAMP was as effective as Dex and E2b in
inducing ANXA1 synthesis (Fig. 5A/D). Furthermore,
the cAMP antagonist Rp-8-Br-cAMPS effectively pre-
vented ANXA1 synthesis in response to either one of
those stimuli (Fig. 5E/G). Hence, these results
indicate that cAMP is also part of the signaling
pathway that leads to ANXA1 synthesis in CCRF-
CEM cells stimulated with either Dex or E2b. More-
over, the ability of Rp-8-Br-cAMPS to inhibit both
CREB activation and ANXA1 expression, induced by
either Dex, E2b or dBcAMP, strongly suggests that
CREB is required for and mediates ANXA1 transcrip-
tion in response to those stimuli. The ability of
dBcAMP to activate both CREB and ANXA1 synthesis
further supports this conclusion.
Members of the MAPK family, namely the p38
MAPK, have been implicated in the phosphorylation
and subsequent activation of CREB in response to
several stimuli.28,29,46 On the contrary, some reports
indicate that Dex and E2b can up-regulate p38 MAPK
activity.3638 To further elucidate the signaling me-
chanisms involved in Dex-induced and E2b-induced
CREB activation and ANXA1 synthesis, we evaluated
the role of the p38 MAPK in those processes by using
the pyrydinyl imidazole compound SB203580, which
is a specific inhibitor of this kinase.4143 The results
obtained show that SB203580 effectively prevented
the activation of CREB (Fig. 6) and the synthesis of
ANXA1 (Fig. 5H/J) induced by Dex, E2b and
dBcAMP. Therefore, the activity of the p38 MAPK
seems to be indispensable for CREB activation and
ANXA1 synthesis to occur in response to Dex, E2b
and dBcAMP. These results also indicate that CREB
mediates ANXA1 expression induced by either one of
these stimuli, in CCRF-CEM cells.
The involvement of CREB on ANXA1 expression
induced by Dex, E2b or dBcAMP is further supported
by the observation that two different agents,
SB203580 and Rp-8-Br-cAMPS, acting by distinct
mechanisms, were equally effective in preventing
these processes. Furthermore, since SB203580 was
also effective in preventing dBcAMP-induced CREB
activation and ANXA1 synthesis, these results also
indicate that, in CCRF-CEM cells, the p38 MAPK
mediates those cAMP-induced responses. These re-
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sults are in agreement with several studies that
indicate the p38 MAPK can be a downstream target
of cAMP, thus participating in cAMP-dependent gene
transcription, although the nature of the kinases that
link cAMP to the p38 MAPK are still unknown.47,48
The ability of Dex and E2b to activate CREB
through a signalling pathway involving cAMP and
the p38 MAPK, as we observed in the present study,
may also be implicated in other effects of GC
hormones, besides ANXA1 synthesis. For instance,
the p38 MAPK and the cAMP-dependent PKA are
required for COX-2 expression in various cell
types.4951 Therefore, it would be possible that these
hormones could also induce COX-2 expression in
CCRF-CEM cells. Although we did not address this
question directly, various studies have shown that GC
hormones, namely Dex, reduce COX-2 expression,
which, at least in some of those cells, is mediated by
ANXA1.68 The ability of Dex to inhibit COX-2
expression can be an important mechanism under-
lying the anti-inflammatory actions of GC and their
inhibitory effect on ceil proliferation. In fact, it was
shown that the ability of Dex to inhibit the synthesis
of prostaglandins by COX-2 is mediated by ANXA1,
leading to the inhibition of cell proliferation.8 On the
contrary, E2b seems to have a dual role on COX-2
expression. In high concentrations, as those used in
the present work, this hormone negatively modulates
COX-2 expression, whereas in lower concentrations
it can up-regulate COX-2 synthesis.52,53 Regardless of
these discrepancies, several studies indicate that
other transcription factors besides CREB, namely
nuclear factor-kB, are required for COX-2 synthesis
in different cells and in response to a variety of
stimuli.50,55 Interestingly, we have recently observed
that Dex (1 mM) inhibits nuclear factor-kB activity in
CCRF-CEM cells,55 which suggests that, although
activating CREB, Dex and E2b cannot induce COX-2
expression in CCRF-CEM cells.
We have previously observed that neither the GC
antagonist RU486 nor the oestrogen antagonist ICI
182,780 can prevent the synthesis of ANXA1, in
response to Dex and E2b, respectively, in CCRF-
CEM cells.4,16 Thus, the ability of Dex and E2b to
induce ANXA1 synthesis seems to be independent of
genomic mechanisms, mediated by the classical GC
and oestrogen receptors, respectively. Instead, this
action of both steroids may involve their binding to
membrane GC or oestrogen receptors12,5658 or
alternatively, it may be mediated by non-specific
interactions with the plasma membrane of CCRF-CEM
cells.59,60
In summary, the results presented here suggest
that, in CCRF-CEM cells, Dex-induced and E2b-
induced ANXA1 expression requires the activation
of the transcription factor CREB, which in turn seems
to be mediated by cAMP and the p38 MAPK. These
findings also suggest that, besides the nuclear steroid
hormone receptors, other transcription factors,
namely CREB, may play important roles in mediating
the anti-inflammatory actions of GC and oestrogen
hormones.
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